Indication
Multiple Myeloma
The Multiple Myeloma pipeline: 167 tracked drugs, 23 approved for this indication.
23 approved / phase 425 Phase 31 Phase 2/311 Phase 243 Phase 1/255 Phase 19 preclinical / unstaged
Compare the share prices of listed companies in Multiple Myeloma →
Total attributable cost
$13.7B
$67,608/patient
Drug spend
$6.7B
$33,012/patient
49% of total cost is drugs
All stages, prevalent population (2023 SEER estimate) · US